Effect of calcitriol and age on recovery from hypocalcemia in hemodialysis patients.

[1]  R. Lindsay,et al.  Resistance to Bone Resorbing Effects of PTH in Black Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  E. Lonergan,et al.  Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men. , 1997, The American journal of physiology.

[3]  E. Ritz,et al.  Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. , 1996, The Journal of clinical endocrinology and metabolism.

[4]  E. Aguilera-Tejero,et al.  Hysteresis of the PTH‐calcium curve during hypocalcemia in the dog: Effect of the rate and linearity of calcium decrease and sequential episodes of hypocalcemia , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  A. Felsenfeld,et al.  The set point of calcium--another view. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  E. Lonergan,et al.  Aging and renal responsiveness to parathyroid hormone in healthy men. , 1996, The Journal of clinical endocrinology and metabolism.

[7]  M. Burritt,et al.  Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. , 1996, The Journal of clinical endocrinology and metabolism.

[8]  J. Bover,et al.  The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients. , 1996, Kidney international.

[9]  H. Malluche,et al.  Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  J. Souberbielle,et al.  Relationship between serum beta 2-microglobulin, bone histology, and dialysis membranes in uraemic patients. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  J. Bover,et al.  Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. , 1995, Kidney international.

[12]  D Hernández,et al.  Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. , 1995, Kidney international.

[13]  J. Bover,et al.  Studies in a hemodialysis patient indicating that calcitriol may have a direct suppressive effect on bone. , 1995, Nephron.

[14]  E. Bonucci,et al.  Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. , 1994, Kidney international.

[15]  G. Segre,et al.  Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. , 1994, Kidney international.

[16]  H. Malluche,et al.  Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. , 1994, Kidney international.

[17]  M. Burritt,et al.  Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. , 1994, The Journal of clinical endocrinology and metabolism.

[18]  J. Cunningham,et al.  Parathyroid sensing of the direction of change of calcium in uremia. , 1993, Kidney international.

[19]  F. Llach,et al.  Parathyroid gland function in chronic renal failure. , 1993, Kidney international.

[20]  J. Bover,et al.  Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  A. Felsenfeld,et al.  Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease. , 1991, Journal of the American Society of Nephrology : JASN.

[22]  F. Llach,et al.  The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. , 1991, Journal of the American Society of Nephrology : JASN.

[23]  P. Grützmacher,et al.  Altered pattern of calcium kinetics in hemodialysis patients after parathyroidectomy. , 1990, ASAIO Transactions.

[24]  R. Dunlay,et al.  Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. , 1989, Kidney international.

[25]  E. Brown,et al.  Hysteresis in the relationship between serum ionized calcium and intact parathyroid hormone during recovery from induced hyper- and hypocalcemia in normal humans. , 1989, The Journal of clinical endocrinology and metabolism.

[26]  Keith C. Norris,et al.  Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. , 1989, The New England journal of medicine.

[27]  E. Brown,et al.  Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. , 1988, The Journal of clinical endocrinology and metabolism.

[28]  E. Bonucci,et al.  Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. , 1986, Mineral and electrolyte metabolism.

[29]  H. Harter,et al.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. , 1984, The Journal of clinical investigation.

[30]  B. Nordin,et al.  A calcium-infusion test. II. Four-hr. skeletal retention data for recognition of osteoporosis. , 1956, Lancet.